1. Müller M, dela Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother. 2004;48(5):1441-1453.
2. Pai MP, Cottrel MLl, Bertino JS. Pharmacokinetics and Pharmacodynamics of Antiinfective Agents. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas and Bennett’s Principles and
Practice of Infectious Diseases. 9th edition. Philadelphia, PA; 2020
3. Buxton ILO. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. In: Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman and Gilman’s the
Pharmacological Basis of Therapeutics. 13th edition. New York: McGraw-Hill; 2018
4. Blumenthal DK. Pharmacodynamics: molecular mechanisms of drug action. In: Brunton LL, Hilal- Dandan R, Knollman BC, eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics.
13th edition. New York: McGraw-Hill; 2018
5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–12.
6. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007;45:S89–S95
7. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev. 2011;24:71–109.
8. Rodvold KA, Yoo L, George JM. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antifungal, antitubercular, and miscellaneous anti-infective agents. Clin
Pharmacokinet. 2011;50:637–664.
9. Gümüștaș T, Küçük N, Melli M. Antibiyotik Tedavisinde Farmakokinetik/Farmakodinamik Yaklașımın Önemi. J Ankara Univ Fac Med. 2018;71(1):23-29.
10. Onufrak NJ, Forrest A, Gonzalez D. Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing. Clin Ther. 2016;38(9):1930-1947.
11. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am. 2009;23(4):791-vii.
12. Brown KC, Kashuba AD. Mechanisms of drug interactions, I: absorption, metabolism and excretion. In: Piscitelli SC, Rodvold KA, Pai MP, eds. Drug Interactions in Infectious Diseases. 3rd
ed. New York: Humana Press; 2011:11–42.
13. Toutain PL, Bousquet-Mélou A. Volumes of distribution. J Vet Pharmacol Ther. 2004;27:441–453.
14. Gandhi A, Moorthy B, Ghose R. Drug disposition in pathophysiological conditions. Curr Drug Metab. 2012;13:1327–1344.
15. Craig WA, Welling PG. Protein binding of antimicrobials: clinical pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1977;2:252–268.
16. Udy AA, Roberts JA, Lipman J. Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med. 2013;39(12):2070-2082.
17. Song Y, Li C, Liu G et al. Drug-metabolizing cytochrome P450 enzymes have multifarious influences on treatment out- comes. Clin Pharmacokinet 2021;60(5):585601.
18. Zhao M, Ma J, Li M et al. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci 2021;22(23).
19. Shah BM, Schafer JJ, Priano J, Squires KE. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013;33:1107–1116.
20. Vieira MD, Kim MJ, Apparaju S, et al. PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways.
Clin Pharmacol Ther. 2014;95:550–557.
21. Asín-Prieto E, Rodríguez-Gascón A, Isla A. Applications of the pharmacokinetic/pharmacodynamic (PK/PD) analysis of antimicrobial agents. J Infect Chemother. 2015;21(5):319-329.
22. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis. 2004;38:864–870.
23. Turnidge J, Patterson DL. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev. 2007;20:391–408.
24. Martinez MN, Papich MG, Drusano GL. Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target. Antimicrob
Agents Chemother. 2012;56:2795–2805.
25. Torella JP, Chait R, Kishony R. Optimal drug synergy in antimicrobial treatments. PLoS Comput Biol. 2010;6:e1000796.
26. Mouton, JW, Muller AE, Canton R, Giske CG, Kahlmeter G, Turnidge, J. MIC-based dose adjustment: Facts and fables. J. Antimicrob. Chemother. 2018, 73, 564–568.
27. Roberts, J.A.; Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 2009, 37, 840–851
28. Simner PJ, Miller L. Understanding Pharmacokinetics (PK) and Pharmacodynamics (PD). AST News Update.2018;3(1):5-8
29. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimum inhibitory concentration.
J Infect Dis. 1987;155:93–99.
30. 34. Deziel-Evans JM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm. 1986;5:319–324.
31. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis. 1991;74:63–70.
32. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother. 1999;43:79–86